

— BIOPHEN™ HEPARIN ASSAYS · ANTI-XA & ANTI-IIA · HYPHEN BIOMED

Heparin potency, chromogenic — *anti-Xa* *and anti-IIa.*

Heparin and LMWH monitoring and potency rest on chromogenic **anti-Factor Xa** and **anti-Factor IIa** methods. The **BIOPHEN™ heparin range** covers both — two-stage anti-Xa and anti-IIa assays plus a kinetic anti-IIa method — all USP/EP-aligned, on plasma or purified systems, manual or automated. Distributed by Aniara in **North America and the Nordic & Baltic states.**

CHROMOGENIC HEPARIN ASSAYS · HYPHEN BIOMED

BIOPHEN™ Heparin Assays

Two-stage chromogenic · USP/EP-aligned

- **Heparin Anti-Xa** (2 stages) — chromogenic anti-FXa potency. A221005.
- **Heparin Anti-IIa** (2 stages) — chromogenic anti-FIIa potency. A220005.
- **Heparin Anti-IIa** (kinetics) — kinetic anti-IIa method for throughput. A221020.
- Measures **UFH & LMWH**; plasma or purified systems; manual or automated.
- Report **anti-Xa, anti-IIa and the anti-IIa/anti-Xa ratio** to monograph.

A221005 · A220005 · A221020

UFH & LMWH

WHY ANTI-XA AND ANTI-IIA

The USP adopted the **anti-IIa method** and the **anti-IIa/anti-Xa ratio** — running both characterizes UFH and LMWH fully, not just anti-Xa.

The **kinetic anti-IIa** option adds throughput for routine monitoring without leaving the chromogenic platform.

Two-stage chromogenic — a defined excess of enzyme, a clean inverse-proportional readout on standard analyzers.

— WHERE IT IS USED

UFH & LMWH potency

Anti-Xa monitoring

Anti-IIa / ratio

Lot release (USP/EP)

Plasma or purified

Manual or automated

Pharma heparin QC

Routine heparin assays

Standardized to monograph

The two-stage method: sample heparin + antithrombin neutralizes a measured excess of Factor Xa (anti-Xa) or thrombin (anti-IIa); residual enzyme cleaves a chromogenic substrate, color **inversely proportional** to heparin potency. Aligned to **USP <208>** and **Ph. Eur.**; calibrate against UFH/LMWH references traceable to the WHO International Standard.

Regulatory: BIOPHEN™ Heparin Anti-Xa (A221005), Anti-IIa (A220005) and Anti-IIa kinetics (A221020) are manufactured by HYPHEN BioMed. Two-stage chromogenic anti-Factor Xa and anti-Factor IIa methods for UFH and LMWH, aligned to USP <208> and the corresponding European Pharmacopoeia methods; regulatory status (RUO / CE-IVD) varies by configuration and region. Distributed by Aniara Diagnostica in **North America and the Nordic & Baltic states.** Pack sizes and pricing on request. © 2026 Aniara Diagnostica, Inc.